JW Pharmaceutical Corporation
シンボルマーク: 001065.KS
KSC
29450
KRW今日の市場価格
18.2050
PER（株価収益率
-0.5003
PEGレシオ
708.70B
MRK キャップ
- 0.01%
DIV利回り
JW Pharmaceutical Corporation (001065-KS) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 370559.84 | 92838 | 149678.7 | 65666.1 | |||||||||||||||||
balance-sheet.row.short-term-investments | 282046.71 | 76929.2 | 115780.8 | 32299.6 | |||||||||||||||||
balance-sheet.row.net-receivables | 692398.22 | 173629.3 | 162146.2 | 192840 | |||||||||||||||||
balance-sheet.row.inventory | 456503.25 | 106091.4 | 111668.4 | 102527.6 | |||||||||||||||||
balance-sheet.row.other-current-assets | 11337.77 | 5532.7 | 1963.7 | 5417.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 1530799.07 | 378091.4 | 425457.1 | 366451.5 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 624681 | 155723.7 | 123048.1 | 118392.3 | |||||||||||||||||
balance-sheet.row.goodwill | 11794.82 | 1404.5 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 92583.31 | 28952 | 16266.2 | 21473.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 104378.13 | 30356.4 | 16266.2 | 21473.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 20291.53 | 52498.2 | -81554 | 69814.7 | |||||||||||||||||
balance-sheet.row.tax-assets | 89655.86 | 20623.3 | 21811.3 | 20802.2 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 261266.16 | 7745.9 | 122944.1 | 36119.4 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 1100272.68 | 266947.4 | 202515.7 | 266601.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 2631071.75 | 645038.8 | 627972.8 | 633053.1 | |||||||||||||||||
balance-sheet.row.account-payables | 262951.71 | 73847.2 | 82907.9 | 51642.9 | |||||||||||||||||
balance-sheet.row.short-term-debt | 667547.61 | 117404.6 | 207693 | 123074.6 | |||||||||||||||||
balance-sheet.row.tax-payables | 57750.41 | 11113.5 | 13983.9 | 29008.6 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 197297.36 | 30000 | 1849.3 | 122070.1 | |||||||||||||||||
Deferred Revenue Non Current | 1431.95 | 1325.4 | 0 | -13199.8 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 5294.44 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 206288.74 | 89585.4 | 82814.9 | 35045.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 309778.22 | 92671.2 | 22082.6 | 161836 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 112201.29 | 22875.8 | 3102.6 | 2600.9 | |||||||||||||||||
balance-sheet.row.total-liab | 1624750.34 | 379598.3 | 402213.7 | 444513.6 | |||||||||||||||||
balance-sheet.row.preferred-stock | 15209.45 | 3173.6 | 3973 | 3352.6 | |||||||||||||||||
balance-sheet.row.common-stock | 229188.67 | 57925.9 | 55445.2 | 53849.8 | |||||||||||||||||
balance-sheet.row.retained-earnings | 391080.62 | 92612 | 89129.8 | 58594.7 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 82131.39 | 53896.2 | 51771.8 | 52070.7 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 303426.98 | 57832.7 | 40034.3 | 33327 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 1021037.11 | 265440.5 | 240354.1 | 201194.8 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2631071.75 | 645038.8 | 627972.8 | 633053.1 | |||||||||||||||||
balance-sheet.row.minority-interest | -14715.71 | 0 | -14595.1 | -12655.2 | |||||||||||||||||
balance-sheet.row.total-equity | 1006321.4 | 265440.5 | 225759 | 188539.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 2631071.75 | - | - | - | |||||||||||||||||
Total Investments | 302338.24 | 129427.3 | 34226.8 | 102114.3 | |||||||||||||||||
balance-sheet.row.total-debt | 887720.78 | 170280.4 | 209542.3 | 245144.7 | |||||||||||||||||
balance-sheet.row.net-debt | 799207.66 | 154371.6 | 175644.4 | 211778.2 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 37151.21 | 35096 | 29852.6 | -1441.5 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 22574.6 | 22444.6 | 16836.3 | 16111.7 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | -20262.51 | -20262.5 | -6169.7 | -46055.8 | |||||||||||||||||
cash-flows.row.account-receivables | -3162.23 | -3162.2 | -4352.5 | -41296.6 | |||||||||||||||||
cash-flows.row.inventory | 8916.8 | 8916.8 | -11541.3 | -2655.1 | |||||||||||||||||
cash-flows.row.account-payables | -9535.56 | -9535.6 | 31652.3 | 3729.7 | |||||||||||||||||
cash-flows.row.other-working-capital | -16481.52 | -16481.5 | -21928.1 | -5833.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 47693.94 | 49879.1 | 16245.2 | 49509.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 87157.24 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38561.91 | -42967.2 | -12352.5 | -12901.6 | |||||||||||||||||
cash-flows.row.acquisitions-net | -14325.59 | -12034 | -40.9 | 385 | |||||||||||||||||
cash-flows.row.purchases-of-investments | -61344 | -61344 | -73817.4 | -140023.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 69604.03 | 69604 | 47473.7 | 141101.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | -19152.8 | -17093.1 | 19817.9 | -11430.8 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -63780.27 | -63834.3 | -18919.2 | -22869.2 | |||||||||||||||||
cash-flows.row.debt-repayment | -216351.12 | -28189.8 | -177004.4 | -98658.1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 7880.94 | -3873 | 10000 | 398.5 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -260.87 | -260.9 | -281.6 | -412.3 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -8813.7 | -7352 | -7149.5 | |||||||||||||||||
cash-flows.row.other-financing-activites | 176299.39 | -54 | 137730.5 | 133023 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -41245.33 | -41191.3 | -36907.5 | 27201.6 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -120.69 | -120.7 | -406.4 | 458.7 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -17989.06 | -17989.1 | 531.4 | 22915.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 88513.13 | 15908.9 | 33897.9 | 33366.5 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 106502.18 | 33897.9 | 33366.5 | 10451.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 87157.24 | 87157.2 | 56764.4 | 18124 | |||||||||||||||||
cash-flows.row.capital-expenditure | -38561.91 | -42967.2 | -12352.5 | -12901.6 | |||||||||||||||||
cash-flows.row.free-cash-flow | 48595.33 | 44190 | 44411.9 | 5222.4 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 748526.71 | 748526.7 | 684351.1 | 606584.9 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 412984.31 | 412854.3 | 396396.6 | 372208.6 | |||||||||||||||||
income-statement-row.row.gross-profit | 335542.4 | 335672.4 | 287954.5 | 234376.3 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 33671.36 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 204703.62 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 35443.42 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -253431.49 | -36136.8 | 64701.4 | 67954.7 | |||||||||||||||||
income-statement-row.row.operating-expenses | -2317.17 | 238911.4 | 225175.5 | 203176.5 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 474255.45 | 651765.7 | 621572 | 575385.1 | |||||||||||||||||
income-statement-row.row.interest-income | 5893.15 | 5893.1 | 5321.5 | 1654.8 | |||||||||||||||||
income-statement-row.row.interest-expense | 9617.04 | 12561.7 | 9386.8 | 7336.7 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 35443.42 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -45650.78 | -42545.6 | -17598.9 | -10667.2 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -253431.49 | -36136.8 | 64701.4 | 67954.7 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -45650.78 | -42545.6 | -17598.9 | -10667.2 | |||||||||||||||||
income-statement-row.row.interest-expense | 9617.04 | 12561.7 | 9386.8 | 7336.7 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 179363.79 | 22444.6 | 19571.5 | 16180.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 279325.21 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 99961.42 | 96761 | 62960.9 | 31199.8 | |||||||||||||||||
income-statement-row.row.income-before-tax | 54310.64 | 54215.4 | 45362 | 20532.7 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 16406.19 | 16406.2 | 15509.4 | 21974.1 | |||||||||||||||||
income-statement-row.row.net-income | 37006.33 | 37006.3 | 31891.7 | -1441.5 |
よくある質問
JW Pharmaceutical Corporation001065.KS 総資産とは何ですか？
JW Pharmaceutical Corporation (001065.KS) 総資産は 645038796101.000.
企業の年間売上高とは？
年間収益は 389220837356.000である.
企業の利益率は？
利益率は 0.448 である.
企業のフリーキャッシュフローとは？
フリーキャッシュフローは 2124.292.
企業の純利益率は？
純利益率は 0.049 である.
企業の総収入は？
総収入は 0.134 である.
JW Pharmaceutical Corporation (001065.KS) 純利益（純利益）とは何ですか？
純利益（純利益）は 37006333990.000.
負債総額は？
負債合計は 170280439662.000 である.
営業費用はいくらですか？
営業費用は 238911370958.000 である.
会社の現金はいくらですか？
企業の現金は 15908868301.000 である.